JNJ Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 50.24% compared to Johnson & Johnson's net margin of 19.72%. Johnson & Johnson's return on equity of 30.18% beat Gilead Sciences's return on equity of 32.29%.

Johnson & Johnson has a consensus price target of $169.14, signalling upside risk potential of 9%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 7.14%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, analysts believe Johnson & Johnson is more attractive than Gilead Sciences.

Johnson & Johnson has a beta of 0.414, which suggesting that the stock is 58.579% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 3.24%. Gilead Sciences offers a yield of 2.86% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Johnson & Johnson's net income of $11B is higher than Gilead Sciences's net income of $1.3B. Notably, Johnson & Johnson's price-to-earnings ratio is 17.26x while Gilead Sciences's PE ratio is 22.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.21x versus 4.79x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 50.24% compared to Johnson & Johnson's net margin of 21.68%. Johnson & Johnson's return on equity of 30.18% beat Eli Lilly and's return on equity of 78.25%.

Johnson & Johnson has a consensus price target of $169.14, signalling upside risk potential of 9%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 23.39%. Given that Eli Lilly and has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly and is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.414, which suggesting that the stock is 58.579% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 3.24%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Eli Lilly and quarterly revenues of $12.7B. Johnson & Johnson's net income of $11B is higher than Eli Lilly and's net income of $2.8B. Notably, Johnson & Johnson's price-to-earnings ratio is 17.26x while Eli Lilly and's PE ratio is 62.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.21x versus 14.22x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 50.24% compared to Johnson & Johnson's net margin of 32.71%. Johnson & Johnson's return on equity of 30.18% beat Merck &'s return on equity of 39.02%.

Johnson & Johnson has a consensus price target of $169.14, signalling upside risk potential of 9%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 24.86%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.414, which suggesting that the stock is 58.579% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 3.24%. Merck & offers a yield of 3.93% to investors and pays a quarterly dividend of $0.81 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Merck & quarterly revenues of $15.5B. Johnson & Johnson's net income of $11B is higher than Merck &'s net income of $5.1B. Notably, Johnson & Johnson's price-to-earnings ratio is 17.26x while Merck &'s PE ratio is 11.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.21x versus 3.24x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 50.24% compared to Johnson & Johnson's net margin of -907.48%. Johnson & Johnson's return on equity of 30.18% beat Moderna's return on equity of -29.23%.

Johnson & Johnson has a consensus price target of $169.14, signalling upside risk potential of 9%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 50.7%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.414, which suggesting that the stock is 58.579% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 3.24%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Moderna quarterly revenues of $107M. Johnson & Johnson's net income of $11B is higher than Moderna's net income of -$971M. Notably, Johnson & Johnson's price-to-earnings ratio is 17.26x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.21x versus 3.91x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.